Main Conference Day 2 - PT (Pacific Time, GMT-08:00)
Main Conference Day 2
- PT (Pacific Time, GMT-08:00)
6:30am - 7:15am45 mins
Fun Run on San Diego Harbor- Meet in Marriott Marquis Foyer
7:15am - 7:30am15 mins
Registration
7:30am - 8:00am30 mins
Scientific Breakfast Briefing #1
Alloy Therapeutic Scientific Breakfast Briefing
8:10am - 8:15am5 mins
Track 1: Novel Bispecific and Multispecific Antibodies
Co-Chairs’ Remarks - Novel Bispecific and Multispecific Antibodies
- Janine Schuurman, Ph.D. - Biotech Consultant, Lust for Life Science
- James Ernst, Ph.D. - Vice President, Development Sciences; Head of Protein Sciences & Technology, Xencor
8:10am - 8:15am5 mins
Track 2: Engineering Innovative Formats & Scaffolds
Co-Chairs' Remarks - Engineering Innovative Formats & Scaffolds
- Sally Ward, PhD - Professor and Director, University of Southampton
- Karen Silence, PhD - Head Preclinical Product Development, Argenx
8:15am - 8:45am30 mins
Track 1: Novel Bispecific and Multispecific Antibodies
Selective Multifunctional Antibodies to Combat Disease
- Paul Parren, PhD - Founder and CSO, Gyes BV
8:15am - 8:45am30 mins
Track 2: Engineering Innovative Formats & Scaffolds
Emerging Heuristics for Engineering Knottins and Cyclins by Yeast Display
- Karl Dane Wittrup, Ph.D. - C.P. Dubbs Professor in Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology
8:45am - 9:15am30 mins
Track 1: Novel Bispecific and Multispecific Antibodies
Leveraging Inherent Proximity to Develop Novel Bispecific ADCs
- Pamela Holland, PhD - Senior Vice President, Biology, InduPro
8:45am - 9:15am30 mins
Track 2: Engineering Innovative Formats & Scaffolds
Positive Allosteric Modulation of Immune Checkpoint Complexes with Nanobodies as a New Mode of Therapeutic Intervention in Immunotherapy
- Jan Steyaert, PhD - Scientific Director, Vrije Universiteit Brussel & VIB
9:15am - 9:45am30 mins
Track 1: Novel Bispecific and Multispecific Antibodies
Targeting Glycans for Cancer Immunotherapy
- Jessica Stark, PhD - Assistant Professor of Biological Engineering, MIT
9:15am - 9:45am30 mins
Track 2: Engineering Innovative Formats & Scaffolds
ADAx-A Novel Platform for Overcoming Immunogenicity in Biologics
- Sandra DePorter, PhD - Senior Director, Discovery Biology, Adaxion Therapeutics
9:45am - 10:30am45 mins
Networking Refreshment Break, Exhibit and Poster Viewing
10:30am - 11:00am30 mins
Track 1: Novel Bispecific and Multispecific Antibodies
DONQ52: A Broadly Cross-Reactive Neutralizing Antibody against Multiple Gluten peptide/HLA-DQ2.5 Complexes for Treatment of Celiac Disease
- Yuri Teranishi-Ikawa - Principal Scientist, Discovery Biologics, Chugai Pharmaceutical Co., Ltd.
10:30am - 11:00am30 mins
Track 2: Engineering Innovative Formats & Scaffolds
ANKET Technology
- Eric Vivier, Ph.D. - SVP and Chief Scientific Officer, Innate Pharma
11:00am - 11:30am30 mins
Track 1: Novel Bispecific and Multispecific Antibodies
Bispecific Antibody Discovery at Surfaceome Scale
- Greg Lazar, Ph.D. - Co-Founder and Chief Technology Officer, Dualitas Therapeutics
11:00am - 11:30am30 mins
Track 2: Engineering Innovative Formats & Scaffolds
Precision Cell Depletion for Autoimmune Disease- T cell Engagers and Beyond
- Ricardo Grieshaber-Bouyer, MHBA - Professor of Clinical Systems Immunology, FAU Erlangen-Nürnberg
11:30am - 12:00pm30 mins
Track 1: Novel Bispecific and Multispecific Antibodies
SOR102 is a Novel, Orally-Administered Anti-TNF/IL-23 Domain Antibody Therapy that Drives Clinical and Pharmacodynamic Responses in the Colonic Tissue of Ulcerative Colitis Patients
- Kevin Roberts - Senior Director of Research, Sorriso Pharmaceuticals
11:30am - 12:00pm30 mins
Track 2: Engineering Innovative Formats & Scaffolds
Agonistic Antibodies for GPCR Modulation: Unlocking New Therapeutic Avenues in Obesity
- Francis Santens, PhD - Principal Scientist Molecular Engineering, Confo Therapeutics
12:05pm - 12:35pm30 mins
Scientific Briefing 1
Human Antibody Discovery and Engineering: The Adimab Way
- Aaron Sato, PhD - Chief Strategy Officer, Adimab
12:05pm - 12:35pm30 mins
Scientific Briefing 2
Comprehensive Assessment of Fc Effector Function Modulation Across Diverse Antibody Formats
- Shashi Jatiani, PhD - Director of Research, SeromYx Systems
12:05pm - 12:35pm30 mins
Scientific Briefing 3
Integrating Synthetic Biology and Computer- aided Design to Advance Biologics Production in CHO Cells
- Imroz Ghangas - Vice President of Commercial Sales, Asimov
12:05pm - 12:35pm30 mins
Scientific Briefing 4
neoSwitch™: A Switchable Yeast Platform and Robotic Workflow for VHH & ScFv Discovery
- Gregory Brittingham, PhD - Director of Product, Neochromosome
12:05pm - 12:35pm30 mins
Scientific Briefing 5
Fast-Tracking Antibody Discovery with the Pioneer™ Platform: From GPCRs to Bispecifics
- Birthe Jessen-Park, PhD - Technical Sales Specialist, Bio-Rad
12:35pm - 1:05pm30 mins
Scientific Briefing 1
T-Body: A Novel Trispecific Antibody Platform to Accelerate and De-Risk Drug Discovery
- Nicholas Marshall, PhD - Head of Protein Sciences, Invenra
12:35pm - 1:05pm30 mins
Scientific Briefing 3
Mosaic Biosciences Scientific Briefing
12:35pm - 1:05pm30 mins
Scientific Briefing 4
Available for Sponsorship. Contact Blake Shuka @ blake.shuka@informa.com
12:35pm - 1:05pm30 mins
Scientific Briefing 5
Available for Sponsorship. Contact Blake Shuka @ blake.shuka@informa.com
1:05pm - 2:25pm80 mins
Networking Luncheon, Exhibit and Poster Viewing
Networking Luncheon, Exhibit and Poster Viewing
1:30pm - 1:40pm10 mins
Technology Showcase Presentations in the Exhibit Hall
KinExA in the Era of AI and Biologics Innovation
- Madelynn Grier, PhD - Staff Scientist, Sapidyne Instruments
1:40pm - 1:50pm10 mins
Technology Showcase Presentations in the Exhibit Hall
Gator Bio Technology Showcase
1:50pm - 2:00pm10 mins
Technology Showcase Presentations in the Exhibit Hall
Gyros Technology Showcase
2:00pm - 2:10pm10 mins
Technology Showcase Presentations in the Exhibit Hall
Ailux Biologics Technology Showcase
2:10pm - 2:20pm10 mins
Technology Showcase Presentations in the Exhibit Hall
Amazon Technology Showcase
2:25pm - 2:30pm5 mins
Track 1: Advanced In Vivo Antibody Discovery
Co-Chairs’ Remarks - Advanced In Vivo Antibody Discovery
- Jenna Guthmiller, PhD - Assistant Professor, Department of Immunology, University of Colorado Anschutz Medical Campus
- Laura Walker, PhD - Head of Infectious Disease Biotherapeutics Discovery, Moderna
2:25pm - 2:30pm5 mins
Track 2: Antibody & Protein Therapeutics in Inflammation, Autoimmunity and Allergy
Co-Chairs' Remarks - Antibody & Protein Therapeutics in Inflammation, Autoimmunity and Allergy
- Jo Viney, PhD - Co-Founder and CEO, Seismic Therapeutic
- John Desjarlais, PhD - Chief Scientific Officer, Xencor, Inc.
2:30pm - 3:00pm30 mins
Track 1: Advanced In Vivo Antibody Discovery
Discovery of Monoclonal Antibodies to Prevent Malaria
- Joshua Tan, PhD - Senior Investigator and Chief of the Antibody Biology Unit, NIAID, NIH
2:30pm - 3:00pm30 mins
Track 2: Antibody & Protein Therapeutics in Inflammation, Autoimmunity and Allergy
Suppressing LAG-3+ T cells Using a Bispecific Targeting LAG-3 and the TCR
- Jun Wang, Ph.D. - Assistant Professor, Department of Pathology, NYU Grossman School of Medicine
3:00pm - 3:30pm30 mins
Track 1: Advanced In Vivo Antibody Discovery
Antibody Responses Induced by an RSV Pre-F Encoding mRNA Vaccine
- Carole Henry, PhD - Director of Immunology in Infectious Disease Research, Moderna
3:00pm - 3:30pm30 mins
Track 2: Antibody & Protein Therapeutics in Inflammation, Autoimmunity and Allergy
PRO-XTENTM Masked T cell Engagers; A Novel Therapeutic Approach Enabling Protease-specific Activation of TCEs Only in the Tumor Microenvironment to Mitigate Damage to Healthy Tissues and Reduce Toxicity
- Jennifer Towne, PhD - Vice President Immunology Discovery and External Innovation, Johnson & Johnson
3:30pm - 4:00pm30 mins
Track 1: Advanced In Vivo Antibody Discovery
In Vivo Discovery of Checkpoint Inhibitors
- Cristina Bonorino, PhD - Full Professor, UFCSPA
3:30pm - 4:00pm30 mins
Track 2: Antibody & Protein Therapeutics in Inflammation, Autoimmunity and Allergy
Engineering IBD Therapeutics: Novel High-Affinity mAbs with Extended Half-Life Targeting TL1A and Il-23p19”
- Kendra Avery, PhD - Director, Protein Sciences & Technology, Xencor
4:00pm - 4:45pm45 mins
Networking Refreshment Break, Exhibit and Poster Viewing
Networking Refreshment Break, Exhibit and Poster Viewing
4:10pm - 4:30pm20 mins
Technology Showcase Presentations in the Exhibit Hall
Empowering Single B Cell Monoclonal Antibody Discovery: High-Throughput Plasma B Cell Screening with DPBIO’s CytoSpark®
- Jennifer Sun, PhD - Global Director of Field Application Scientists, DPBIO
4:45pm - 5:15pm30 mins
Track 1: Advanced In Vivo Antibody Discovery
Discovery of Next-Generation Brain Shuttles: Biodistribution Engineering through Multiplexed In Vivo Screening and AI-Guided Protein Design
- Karen Duffy, PhD - Principal Scientist, Manifold Bio
4:45pm - 5:15pm30 mins
Track 2: Antibody & Protein Therapeutics in Inflammation, Autoimmunity and Allergy
Blocking Ion Channel Kv1.3 with KnotBodyTM Molecules to Modulate T cell Function
- John McCafferty, PhD - Chief Technology Officer, Maxion Therapeutics
5:15pm - 5:45pm30 mins
Track 1: Advanced In Vivo Antibody Discovery
Leveraging Immune Organoids to Investigate Antibody-mediated Immunity
- Erika Joloya - Ph.D. Candidate, Laboratory of Lisa Wagar, University of California, Irvine
5:15pm - 5:45pm30 mins
Track 2: Antibody & Protein Therapeutics in Inflammation, Autoimmunity and Allergy
IgE Cleaving Enzymes for Treatment of Allergy and Atopy
- Purvi Mande, PhD - Principal Scientist, Seismic Therapeutic
5:45pm - 6:15pm30 mins
Track 1: Advanced In Vivo Antibody Discovery
Human IGH Germline Gene Diversity and Allele Frequencies in 2486 Individuals from 25 Global Populations Delineated by Ultra-high throughput Genotyping
- Martin Corcoran, PhD - Head of Immunogenetics, Gunilla Karlsson Hedestam, Karolinska Institutet
5:45pm - 6:15pm30 mins
Track 2: Antibody & Protein Therapeutics in Inflammation, Autoimmunity and Allergy
Engineering Trispecific Antibodies for Multiple Cytokine Blockade in Allergic Diseases
- Fang Jin - Principal Scientist, BioMedicine Design, Pfizer
6:15pm - 7:15pm60 mins
Networking Reception, Exhibit and Poster Viewing
* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.